Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: Possible immunotherapy for colorectal carcinomas

British Journal of Cancer

Volumn 84, Issue 1, 2001, Pages 94-99

  Tanaka, H ^a   Tsunoda, T ^a,b   Nukaya, I ^c   Sette, A ^c   Matsuda, K ^a   Umano, Y ^a   Yamaue, H ^a   Takesako, K ^c   Tanimura, H ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Advanced Clinical Research Center   (Japan)

^c TAKARA SHUZO CO LTD   (Japan)

Author keywords

Colorectal carcinoma; CTL; Epitope peptide; HER2 neu

Indexed keywords

CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA A3 ANTIGEN; HLA ANTIGEN CLASS 1; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ALLELE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CAUCASIAN; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; JAPAN; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; METASTASIS; ONCOGENE NEU; PEPTIDE MAPPING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MOTIF; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

COLORECTAL NEOPLASMS; DENDRITIC CELLS; EPITOPE MAPPING; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; PEPTIDE MAPPING; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

EID: 0035138721     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1547     Document Type: Article

References (41)

1. Amplification of HER-2/neu gene in human gastric adenocarcinomas: Colleration with primary site
2. Tumor-inhibitory monoclonal antibodies to the HER-2/neu receptor induce differentiation of human breast cancer cells
3. Recombinant humanized anti-HER-2/neu antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxolubicin against HER-2/neu overexpressing human breast cancer xenographts
4. Tumor antigens recognized by cytotoxic T lymphocytes: Present perspectives for specific immunotherapy
5. Human tumor antigen recognized by T lymphocytes
6. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
7. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific T lymphocytes
8. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes
9. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
10. DNA typing of the HLA-A gene: Population study and identification of four new alleles in Japanese
11. Sequence motifs of human HER-2 proto-oncogene important for peptide binding to HLA-A2
12. Identification of an immunodominant peptide of HER-2/neu protoncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
13. Dendritic cells: Unique leucocyte populations which control the primary immune response
14. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine
15. The expression of p185HER-2/neu correlates with the stage of diseases and survival in colorectal cancer
16. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
17. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide pulsed dendritic cells
18. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules
19. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic lymphocytes
20. Definition of specific peptide motifs for four major HLA-A alleles
21. Prognostic significance of c-erb-B2 amplification in fine needle biopsies of breast cancer patients not operated at diagnosis
22. Migration of human dendritic cells after injection in patients with metastatic malignancies
23. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed antologous antigen presenting cells
24. Vaccination of melanoma patients with peptideor tumor lysate-pulsed dendritic cells
25. Identification of HLA-A24 epitope peptide of carcinoembryonic antigen that induce tumor-reactive cytotoxic T lymphocyte
26. Breast and ovarian cancer specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
27. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
28. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients
29. Proliferating dendritic cell progenitors in human blood
30. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
31. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
32. neu levels in HER-2/neu-transfected human lung cancer cells
33. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells
34. Generation of human cytotoxic T cell specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
35. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
36. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow transfer of T-cell clones from the donor
37. Antibody immunity to the HER-2/neu oncogene protein in patients with colorectal cancer
38. Expression of c-erb-B2 in human pancreatic adenocarcinomas
39. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma
40. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
41. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer